ATE293453T1 - Verbindungen zur behandlung von sexuellen funktionsstörungen - Google Patents

Verbindungen zur behandlung von sexuellen funktionsstörungen

Info

Publication number
ATE293453T1
ATE293453T1 AT00950283T AT00950283T ATE293453T1 AT E293453 T1 ATE293453 T1 AT E293453T1 AT 00950283 T AT00950283 T AT 00950283T AT 00950283 T AT00950283 T AT 00950283T AT E293453 T1 ATE293453 T1 AT E293453T1
Authority
AT
Austria
Prior art keywords
treatment
sexual dysfunction
compounds
phe
arg
Prior art date
Application number
AT00950283T
Other languages
English (en)
Inventor
Christine H Blood
Annette M Shadiack
Joanna K Bernstein
Guy W Herbert
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Application granted granted Critical
Publication of ATE293453T1 publication Critical patent/ATE293453T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
AT00950283T 1999-06-29 2000-06-29 Verbindungen zur behandlung von sexuellen funktionsstörungen ATE293453T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14234699P 1999-06-29 1999-06-29
US19498700P 2000-04-05 2000-04-05
US09/606,501 US6579968B1 (en) 1999-06-29 2000-06-28 Compositions and methods for treatment of sexual dysfunction
PCT/US2000/018217 WO2001000224A1 (en) 1999-06-29 2000-06-29 Compositions and methods for treatment of sexual dysfunction

Publications (1)

Publication Number Publication Date
ATE293453T1 true ATE293453T1 (de) 2005-05-15

Family

ID=27385799

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00950283T ATE293453T1 (de) 1999-06-29 2000-06-29 Verbindungen zur behandlung von sexuellen funktionsstörungen

Country Status (15)

Country Link
US (3) US6579968B1 (de)
EP (1) EP1196184B8 (de)
JP (1) JP4576493B2 (de)
KR (1) KR101021632B1 (de)
AT (1) ATE293453T1 (de)
AU (1) AU783718B2 (de)
BR (1) BR0012200B1 (de)
CA (1) CA2376978C (de)
DE (1) DE60019598T2 (de)
ES (1) ES2235921T3 (de)
HK (1) HK1047881B (de)
MX (1) MXPA02000111A (de)
NZ (1) NZ516030A (de)
PT (1) PT1196184E (de)
WO (1) WO2001000224A1 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
CA2377369A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
EP1409540A2 (de) * 2000-09-27 2004-04-21 The Procter & Gamble Company Melanocortin rezeptor liganden
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
AU2002331064B2 (en) * 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US6873883B2 (en) * 2001-12-26 2005-03-29 Hewlett-Packard Development Company, L.P. Adaptive fan controller for a computer system
US20070004743A1 (en) * 2002-02-25 2007-01-04 Xiao Linda L Intranasal administration of mc4-r agonists
US8043287B2 (en) * 2002-03-05 2011-10-25 Kimberly-Clark Inc. Method of treating biological tissue
DE10228837B4 (de) * 2002-06-27 2016-01-07 Elfriede Rauch Hautkosmetische Zusammensetzung und Verwendung der Zusammensetzung als Hautbräunungsmittel
WO2004005324A2 (en) * 2002-07-09 2004-01-15 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
CA2512434C (en) * 2003-02-26 2012-01-03 Otsuka Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition comprising carrageenan for lung administration
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US20050101535A1 (en) * 2003-05-06 2005-05-12 Rosenstein David H. Use of a synthetic alpha-melanocyte stimulating hormone agonist to decrease steroid induced weight gain
EP1644022A1 (de) * 2003-06-19 2006-04-12 Eli Lilly And Company Verwendungen von melanocortin-3-rezeptor (mc3r) peptidagonisten
EP1644023A2 (de) * 2003-06-19 2006-04-12 Eli Lilly And Company Melanocortin rezeptor 4(mc4) agonisten und ihre anwendungen
EP1670815A2 (de) 2003-09-30 2006-06-21 Novo Nordisk A/S Melanocortinrezeptoragonisten
US7550602B1 (en) * 2004-01-14 2009-06-23 Palatin Technologies, Inc. Small molecule compositions for sexual dysfunction
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
AU2005235422B2 (en) * 2004-04-22 2011-08-11 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders II
TW200626611A (en) * 2004-09-20 2006-08-01 Lonza Ag Peptide cyclisation
WO2006060873A1 (en) * 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Method for restoring reproductive function
NZ565217A (en) * 2005-07-08 2010-03-26 Ipsen Pharma Sas Melanocortin receptor ligands
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
EP1957096A4 (de) * 2005-08-29 2012-03-21 Palatin Technologies Inc Zyklische peptid-isolierung durch sprühtrocknung
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US8247530B2 (en) * 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
CN101092451B (zh) * 2006-06-20 2011-02-09 中国人民解放军军事医学科学院毒物药物研究所 Pt-141和mt-ⅱ的固相合成方法
EP2037927B1 (de) 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
KR20090045945A (ko) 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
CN101195654B (zh) * 2006-12-08 2011-06-15 上海吉尔多肽有限公司 一种美拉诺坦-ⅱ的固相合成方法
ATE524446T1 (de) 2006-12-20 2011-09-15 Boehringer Ingelheim Int Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
WO2008091355A2 (en) * 2007-01-24 2008-07-31 Breathe Pharmaceuticals, Inc. Drug transfer device
CN101280005B (zh) * 2007-04-06 2013-03-13 扬子江药业集团四川海蓉药业有限公司 普美拉肽的制备方法
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
WO2009151714A2 (en) * 2008-03-24 2009-12-17 Palatin Technologies, Inc. Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
WO2009144433A1 (en) * 2008-05-30 2009-12-03 Palatin Technologies, Inc. Methods for selection of melanocortin 4 receptor-specific agents for treatment of obesity
KR101687037B1 (ko) 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
WO2009151383A1 (en) * 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for the treatment of obesity and other diseases associated with melanocortin receptor function
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EP2440572B1 (de) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-gebrückte melanocortinrezeptorspezifische peptide
CA2761607C (en) * 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
BR112012011780A2 (pt) 2009-11-23 2019-09-24 Palatin Technologies, Inc peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
JP5999702B2 (ja) 2009-11-23 2016-09-28 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. メラノコルチン−１受容体特異的環状ペプチド
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
BR112013027222B1 (pt) 2011-06-14 2022-07-12 Ipsen Pharma S.A.S. Composição de liberação sustentada que contém peptídeos como ingrediente ativo
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
FI2916856T4 (fi) 2012-11-05 2024-01-15 Palatin Technologies Inc Bremelanotidin käyttöjä naisen seksuaalisen toimintahäiriön hoidossa
CA2892144C (en) 2012-11-21 2020-04-28 University Of Cincinnati Pharmaceutical compositions and therapeutic methods of use comprising selective agonists of melanocortin 1 receptor
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
US9814755B2 (en) 2014-06-10 2017-11-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of depression and anxiety
US9821023B2 (en) 2014-06-10 2017-11-21 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of central nervous system (CNS) disorders and mood disorders
US20170022252A1 (en) 2014-06-10 2017-01-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
US10550157B2 (en) 2015-10-16 2020-02-04 Arizona Board Of Regent On Behalf Of The University Of Arizona Compositions and methods for treating central nervous system (CNS) disorders and mood disorders
WO2017066769A1 (en) * 2015-10-16 2017-04-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating central nervous system (cns) disorders and mood disorders
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN106243214B (zh) * 2016-08-29 2019-12-10 济南康和医药科技有限公司 一种美拉诺坦ⅰ的制备方法
RU2655763C2 (ru) * 2016-10-24 2018-05-29 Общество С Ограниченной Ответственностью "Айвикс" Фармацевтическая композиция и способ лечения женских сексуальных дисфункций
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
JP7735282B2 (ja) * 2020-02-03 2025-09-08 パラティン テクノロジーズ， インコーポレイテッド 逆アミド結合を持つメラノコルチン受容体に特異的な環状ペプチド
CN115515617A (zh) * 2020-02-03 2022-12-23 帕拉丁科技公司 二胺连接的受体特异性环状肽

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862928A (en) * 1969-07-09 1975-01-28 Akzona Inc Psychopharmacological hexa-peptides containing a d-phenylalanyl residue
BE795788A (nl) * 1972-02-22 1973-08-22 Akzo Nv Werkwijze ter bereiding van peptiden en peptide-derivaten en de toepassing hiervan
US4649191A (en) * 1984-05-10 1987-03-10 Gibson-Stephens Neuropharmaceuticals, Inc. Conformationally constrained alpha-melanotropin analogs with specific central nervous system activity
US4623715A (en) * 1984-10-22 1986-11-18 Hoechst Aktiengeselleschaft Novel peptides which are active on the central nervous system and have an action on the cholinergic system
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
ATE164080T1 (de) 1990-05-10 1998-04-15 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
FR2691465B1 (fr) * 1992-05-25 1995-08-11 Pf Medicament Complexes comprenant au moins un peptide derive de l'alpha msh, peptide, microsphere, medicament et composition galenique les comprenant.
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
WO1994022460A1 (en) * 1993-04-05 1994-10-13 University Patents, Inc. Diagnosis and treatment of erectile dysfunction
US5420109A (en) * 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
FR2735131B1 (fr) * 1995-06-12 1997-08-22 Rech De Pathologie Appliquee S Conjugues d'msh avec un acide gras, leur procede de preparation et leur utilisation a titre de medicament
US5908825A (en) 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
WO1999021571A1 (en) 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
US6228840B1 (en) 1998-02-27 2001-05-08 Edward T. Wei Melanocortin receptor antagonists and modulations of melanocortin receptor activity
EP1076649A4 (de) 1998-04-28 2010-06-02 Trega Biosciences Inc Isoquinolinverbindung, melanocortinrezeptor-liganden und anwendungsverfahren derselben
WO1999064002A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction

Also Published As

Publication number Publication date
ES2235921T3 (es) 2005-07-16
JP2003503357A (ja) 2003-01-28
US6579968B1 (en) 2003-06-17
US6794489B2 (en) 2004-09-21
HK1047881A1 (en) 2003-03-14
CA2376978A1 (en) 2001-01-04
HK1047881B (en) 2005-10-14
JP4576493B2 (ja) 2010-11-10
MXPA02000111A (es) 2003-07-21
EP1196184B8 (de) 2005-06-15
NZ516030A (en) 2004-10-29
KR20020016876A (ko) 2002-03-06
AU783718B2 (en) 2005-12-01
DE60019598D1 (de) 2005-05-25
DE60019598T2 (de) 2005-09-29
EP1196184B1 (de) 2005-04-20
BR0012200B1 (pt) 2013-08-06
EP1196184A4 (de) 2003-05-28
WO2001000224A1 (en) 2001-01-04
CA2376978C (en) 2012-11-20
US20050037951A1 (en) 2005-02-17
US20020107182A1 (en) 2002-08-08
KR101021632B1 (ko) 2011-03-17
PT1196184E (pt) 2005-08-31
AU6340700A (en) 2001-01-31
BR0012200A (pt) 2002-03-26
EP1196184A1 (de) 2002-04-17

Similar Documents

Publication Publication Date Title
ATE293453T1 (de) Verbindungen zur behandlung von sexuellen funktionsstörungen
WO2005014617A3 (en) Cyclic peptide compositions and methods for treatment of sexual dysfunction
CY1107051T1 (el) Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους
GEP20053602B (en) Aripiprazole for Oral Administration
CA2338005A1 (en) Peptide antagonists of zonulin and methods for use of the same
EP1159964A3 (de) Zusammenstellungen und Methoden zur Förderung der Beweglichkeit des Verdauungstrakts
MY106528A (en) Method of treating impotence.
NZ516477A (en) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
BG106008A (en) Novel lhrh antagonists with improved solubility characteristics
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
HUP0001431A2 (hu) Módosított tandem peptid, ezt tartalmazó immunogén gyógyászati készítmény és vakcina az LHRH hormon termelés ellen, és eljárás a sertéshús minőségének javítására
PL360492A1 (en) Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates
IT1244496B (it) Impiego terapeutico dei peptidi della somatostatina.
RU2003127718A (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
MXPA02008870A (es) Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos.
EP1593384A3 (de) Verbindungen zur Behandlung von sexuellen Funktionsstörungen
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
NO894720D0 (no) Farmasoeytisk aktivt protein.
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DE602004019141D1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonin (ivtntt) enthaltende biologisch wirksame peptide
JPH0372044B2 (de)
ATE280584T1 (de) Verwendung von beta interferon zur herstellung eines arzneimittels zur behandlung von ewings sarkom und eoe
UA36167A (uk) Спосіб лікування панкреатиту
ATE323481T1 (de) Verwendung von propionyl-l-carnitin oder dessen pharmakologisch akzeptabler salze zur herstellung eines medikamentes zur behandlung von la peyronie's krankheit
MD1469G2 (ro) Metodă de tratament al şocului combustional

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1196184

Country of ref document: EP